Tsimberidou AM, O'Brien S, Khouri I, Giles FJ, Kantarjian HM, Champlin R, et al. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol. 2006;24(15):2343–51.

Article  CAS  PubMed  Google Scholar 

Wang Y, Tschautscher MA, Rabe KG, Call TG, Leis JF, Kenderian SS, et al. Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. Haematologica. 2020;105(3):765–73.

Article  PubMed  PubMed Central  Google Scholar 

Pistoia V, Roncella S, Di Celle PF, Sessarego M, Cutrona G, Cerruti G, et al. Emergence of a B-cell lymphoblastic lymphoma in a patient with B-cell chronic lymphocytic leukemia: evidence for the single-cell origin of the two tumors. Blood. 1991;78(3):797–804.

Article  CAS  PubMed  Google Scholar 

Klener P, Fronkova E, Berkova A, Jaksa R, Lhotska H, Forsterova K, et al. Mantle cell lymphoma-variant Richter syndrome: detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years. Int J Cancer. 2016;139(10):2252–60.

Article  CAS  PubMed  Google Scholar 

Parikh SA, Rabe KG, Call TG, Zent CS, Habermann TM, Ding W, et al. Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. Br J Haematol. 2013;162(6):774–82.

Article  PubMed  PubMed Central  Google Scholar 

Rossi D, Spina V, Deambrogi C, Rasi S, Laurenti L, Stamatopoulos K, et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood. 2011;117(12):3391–401.

Article  CAS  PubMed  Google Scholar 

Ansell SM, Li CY, Lloyd RV, Phyliky RL. Epstein-Barr virus infection in Richter's transformation. Am J Hematol. 1999;60(2):99–104.

Article  CAS  PubMed  Google Scholar 

Favini C, Talotta D, Almasri M, Andorno A, Rasi S, Adhinaveni R, et al. Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome. Br J Haematol. 2022;198(6):1016–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• Parry EM, Leshchiner I, Guièze R, Johnson C, Tausch E, Parikh SA, et al. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome. Nat Med. 2023;29(1):158–69. In this paper, Dr. Parry et al describe how RT transforms from CLL, deepening our understanding of the transformationm process.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chigrinova E, Rinaldi A, Kwee I, Rossi D, Rancoita PM, Strefford JC, et al. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood. 2013;122(15):2673–82.

Article  CAS  PubMed  Google Scholar 

Rossi D, Cerri M, Capello D, Deambrogi C, Rossi FM, Zucchetto A, et al. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol. 2008;142(2):202–15.

Article  CAS  PubMed  Google Scholar 

Falchi L, Keating MJ, Marom EM, Truong MT, Schlette EJ, Sargent RL, et al. Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood. 2014;123(18):2783–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• Kittai AS, Huang Y, Beckwith KA, Bhat SA, Bond DA, Byrd JC, et al. Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib. Am J Hematol. 2023;98(1):56–65. This is one of the only studies that evaluated RT that had developed on small molecule inhibitors. Highlighting important clinical indications to consider RT development, and poor overall survival even in the era of modern therapy.

Article  CAS  PubMed  Google Scholar 

Miller CR, Ruppert AS, Heerema NA, Maddocks KJ, Labanowska J, Breidenbach H, et al. Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib. Blood Adv. 2017;1(19):1584–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Langerbeins P, Busch R, Anheier N, Dürig J, Bergmann M, Goebeler ME, et al. Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation. Am J Hematol. 2014;89(12):E239–43.

Article  CAS  PubMed  Google Scholar 

NCCN Clinical Practice Guidelines: histologic transformation (Richter’s) and progression. Version 2.2023. Accessed August 18 Tvmracvotg, visit NCCN.org.

Smyth E, Eyre TA, Cheah CY. Emerging therapies for the management of Richter transformation. J Clin Oncol. 2023;41(2):395–409.

Article  CAS  PubMed  Google Scholar 

Rogers KA, Huang Y, Ruppert AS, Salem G, Stephens DM, Heerema NA, et al. A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. Br J Haematol. 2018;180(2):259–66.

Article  CAS  PubMed  Google Scholar 

Al-Sawaf O, Robrecht S, Bahlo J, Fink AM, Cramer P, v Tresckow J, et al. Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials. Leukemia. 2021;35(1):169–76.

Article  CAS  PubMed  Google Scholar 

Elnair R, Ellithi M, Kallam A, Shostrom V, Bociek RG. Outcomes of Richter's transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): an analysis of the SEER database. Ann Hematol. 2021;100(10):2513–9.

Article  PubMed  Google Scholar 

Abrisqueta P, Delgado J, Alcoceba M, Oliveira AC, Loscertales J, Hernández-Rivas JA, et al. Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC). Br J Haematol. 2020;190(6):854–63.

Article  CAS  PubMed  Google Scholar 

Popp HD, Flach J, Brendel S, Ruppenthal S, Kleiner H, Seifarth W, et al. Accumulation of DNA damage and alteration of the DNA damage response in monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. Leuk Lymphoma. 2019;60(3):795–804.

Article  CAS  PubMed  Google Scholar 

Stephens DM, Boucher K, Kander E, Parikh SA, Parry EM, Shadman M, et al. Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration. Haematologica. 2021;106(11):2845–52.

Article  CAS  PubMed  Google Scholar 

Tsang M, Shanafelt TD, Call TG, Ding W, Chanan-Khan A, Leis JF, et al. The efficacy of ibrutinib in the treatment of Richter syndrome. Blood. 2015;125(10):1676–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eyre TA, Schuh A, Wierda WG, Brown JR, Ghia P, Pagel JM, et al. Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1–2 study. Lancet Haematol. 2021;8(12):e912–e21.

Article  CAS  PubMed  Google Scholar 

Al-Sawaf O, Robrecht S, Stumpf J, Fink A-M, Ritgen M, Johansson P, et al. The CLL-RT1 trial: a multicenter phase-2 trial of zanubrutinib, a BTK inhibitor, plus tislelizumab, a PD-1 inhibitor, for patients with Richter transformation. Hematol Oncol. 2021;39(S2).

Appleby N, Eyre TA, Cabes M, Jackson A, Boucher R, Yates F, et al. The STELLAR trial protocol: a prospective multicentre trial for Richter's syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease. BMC Cancer. 2019;19(1):471.

Article  PubMed  PubMed Central  Google Scholar 

Al-Sawaf O, Zhang C, Tandon M, Sinha A, Fink AM, Robrecht S, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21(9):1188–200.

Article  CAS  PubMed  Google Scholar 

Al-Sawaf O, Zhang C, Lu T, Liao MZ, Panchal A, Robrecht S, et al. Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study. J Clin Oncol. 2021;39(36):4049–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. J Clin Oncol. 2018;36(19):1973–80.

Article  CAS  PubMed  Google Scholar 

Seymour JF, Kipps TJ, Eichhorst BF, D’Rozario J, Owen CJ, Assouline S, et al. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. Blood. 2022;140(8):839–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tam CS, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S, et al. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood. 2022;139(22):3278–89.

Article  CAS  PubMed  Google Scholar 

Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35(8):826–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Davids MS, Rogers KA, Tyekucheva S, Wang Z, Pazienza S, Renner SK, et al. Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. Blood. 2022;139(5):686–9.

Article  CAS  PubMed  Pub